Esphera SynBio is a pre-clinical company developing the next generation of exosome-based therapeutics. Their proprietary technology enables the generation of bespoke exosomes by modifying producer cells thereby obviating the need to harvest and then modify exosomes. These designer exosomes can be targeted to specific cell types and engineered to contain one or more therapeutic payloads. Engineered exosomes represent a new and exciting opportunity for drug developers as they offer unique advantages over traditional drug delivery. Esphera is developing a pipeline of exosome-based therapeutics and vaccines to solve for challenges across oncology, cell and gene therapy and infectious disease.

Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


42 in total